Allakos Inc

NASDAQ ALLK

Data sourced from

and

Download Data

Allakos Inc Non-operating Income/Expense 5 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024: 141.33%

Allakos Inc Non-operating Income/Expense 5 year CAGR is 141.33% for the Trailing 12 Months (TTM) ending March 31, 2024. Non-operating Income/Expense refers to the income or expenses generated from non-core business activities, such as investments or one-time gains/losses. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Allakos Inc Non-operating Income/Expense for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 6.49 M, a 21,038.71% change year over year.
Allakos Inc Non-operating Income/Expense for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -31.00 K, a 96.55% change year over year.
Allakos Inc Non-operating Income/Expense for the Trailing 12 Months (TTM) ending March 31, 2021 was USD -899.00 K, a -2,205.13% change year over year.
Allakos Inc Non-operating Income/Expense for the Trailing 12 Months (TTM) ending March 31, 2020 was USD -39.00 K, a 84.27% change year over year.

NASDAQ: ALLK

Allakos Inc

CEO	Dr. Robert Alexander Ph.D.
IPO Date	July 19, 2018
Location	United States
Headquarters	975 Island Drive, Redwood City, CA, United States, 94065
Employees	131
Sector	Healthcare
Industry	Biotechnology

Description

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

Key trends